Why Indian drugmakers are losing pricing power in the US



Powerful buyers, the end of limits on generic Revlimid and fast-fading launches are squeezing Indian drugmakers’ US business. Complex products offer a way to protect pricing power, but developing them requires higher R&D spending and years of investment before they can replace lost revenue.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *